Cognitive performance depends on several biological systems working together. Nootropic peptides target these systems through different but overlapping mechanisms:
Neurotrophic factor signaling. Brain-derived neurotrophic factor (BDNF) is the brain's primary growth signal for maintaining existing neurons and growing new ones. It is active in the hippocampus, cortex, and basal forebrain — areas central to learning, memory, and higher-order thinking. BDNF levels decline with age, and lower BDNF is independently associated with memory impairment in older adults [1]. Several peptides in this guide work by upregulating BDNF production or mimicking its effects.
Synaptogenesis and dendritic spine formation. Memories are encoded in synaptic connections. The more plentiful and well-formed these connections, the greater your brain's capacity for learning and recall. Some peptides promote the formation of new synapses (synaptogenesis) and the growth of dendritic spines — the tiny protrusions on neurons where synapses form.
Neurotransmitter modulation. Dopamine, serotonin, norepinephrine, and GABA regulate attention, mood, motivation, and anxiety. Peptides can influence these systems without the blunt pharmacological effects of traditional drugs.
Neuroprotection. Oxidative stress, inflammation, and excitotoxicity (overstimulation by glutamate) all damage neurons. Neuroprotective peptides reduce these threats, preserving cognitive function as you age.
Neuroplasticity. The brain's ability to reorganize itself — forming new neural pathways in response to learning or injury — is called neuroplasticity. It is not fixed. It can be supported or degraded depending on the biochemical environment.
Semax is a heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) developed at the Russian Academy of Sciences. It is derived from ACTH (adrenocorticotropic hormone) but retains only ACTH's neurotrophic effects — it does not trigger the hormonal activity associated with the parent molecule [2].
Semax is registered as a medicine in the Russian Federation and classified as a nootropic. It has been used clinically in Russia for ischemic stroke, dyscirculatory encephalopathy, optic nerve disease, and for newborns with neurological deficits.
BDNF upregulation. A single application of Semax (50 ug/kg) produced a 1.4-fold increase in BDNF protein levels, a 1.6-fold increase in TrkB tyrosine phosphorylation (the receptor BDNF binds to), a 3-fold increase in exon III BDNF mRNA, and a 2-fold increase in TrkB mRNA in the rat hippocampus [3].
Stroke recovery. In a clinical study of 110 ischemic stroke patients, Semax treatment (6000 mcg/day for two 10-day courses) increased plasma BDNF levels regardless of rehabilitation timing. Higher BDNF levels correlated with faster improvement on the Barthel index (a measure of functional independence), and Semax-treated patients showed better motor performance than controls [4].
Neuroprotection after ischemia. In rats with permanent middle cerebral artery occlusion, Semax increased transcription of BDNF, TrkC, TrkA, NT-3, and NGF — a broad neurotrophic response [5].
Cognitive effects in healthy subjects. A study reported that Semax (250-1000 ug/kg) improved attention and short-term memory and produced EEG changes similar to other neuroprotective drugs [2]. Beyond BDNF, Semax affects dopaminergic and serotonergic signaling, which likely accounts for focus and motivation effects.
Most clinical publications on Semax are in Russian, with only abstracts available in English. This limits critical appraisal of the data. Semax is not FDA-approved and has not been evaluated by the FDA for any indication.
Selank is a synthetic heptapeptide derived from tuftsin, a naturally occurring immunomodulatory peptide. Like Semax, it was developed by Russian researchers and is registered in Russia — classified as an anxiolytic rather than a nootropic [6].
Where Semax targets focus and cognition through BDNF and dopamine, Selank addresses the other side of the cognitive equation: the anxiety, rumination, and emotional noise that degrade mental performance.
Anxiolytic effects without sedation. Clinical studies show Selank has effects similar to benzodiazepine tranquilizers at low doses but without amnesia, withdrawal, or physical dependence [6].
GABAergic neurotransmission. A study examined Selank's effect on 84 genes involved in GABAergic neurotransmission in the rat frontal cortex. Of 77 genes analyzed, 45 showed mRNA changes within one hour of intranasal administration — a broad effect on the brain's primary inhibitory neurotransmitter system [7].
Neurotransmitter modulation. Selank influences norepinephrine, serotonin, and dopamine — three neurotransmitters with direct roles in attention, learning, memory, and cognitive motivation.
Neuroimaging evidence. An fMRI study in 52 healthy participants found that both Selank and Semax altered functional connectivity between the right amygdala and temporal cortical regions, but through distinct patterns — different neural targets for anxiety reduction (Selank) versus cognitive enhancement (Semax) [8].
Selank also shows immunomodulatory properties that may indirectly support cognition by reducing neuroinflammation.
Some practitioners combine the two — Semax for the drive and focus, Selank for the calm that lets you use it productively.
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, developmental code PNB-0408) is an oligopeptide derived from angiotensin IV, developed by researchers at Washington State University. It is perhaps the most potent procognitive peptide discovered — and also one of the most controversial [9].
HGF/c-Met mechanism. Dihexa binds with high affinity to hepatocyte growth factor (HGF) and potentiates its activity at the c-Met receptor. This is a fundamentally different mechanism from most nootropics. HGF/c-Met signaling drives synaptogenesis — the formation of new synaptic connections in the brain [10].
Potency. In a cell culture assay of neurotrophic activity, Dihexa was found to be seven orders of magnitude (approximately 10 million times) more potent than BDNF at promoting new neuronal connections. This number, reported by the original research team at Washington State University, comes from in vitro assays and should be understood in that context — cell culture potency does not directly translate to whole-brain effects [10].
Memory rescue in Alzheimer's models. In APP/PS1 mice (a standard Alzheimer's disease model), oral Dihexa restored spatial learning and cognitive function as measured by the Morris water maze. It increased neuronal cells, elevated synaptophysin (SYP) protein expression, decreased activation of astrocytes and microglia, reduced pro-inflammatory cytokines (IL-1b, TNF-a), and increased the anti-inflammatory cytokine IL-10. These effects were mediated through the PI3K/AKT signaling pathway [11].
Scopolamine-induced amnesia reversal. When rats were made acutely amnesic by scopolamine (a muscarinic receptor antagonist), orally delivered Dihexa reversed the cognitive deficits. Intracerebroventricular delivery of an HGF antagonist blocked Dihexa's procognitive effects, confirming the HGF/c-Met mechanism [10].
Pharmacokinetics. Dihexa is orally bioavailable and crosses the blood-brain barrier — rare among peptides. It has a remarkably long circulating half-life: 12.68 days after IV administration in rats [9].
Dihexa carries a theoretical but serious safety concern. The HGF/c-Met pathway is a key driver in many cancers. Activating this pathway could, in theory, promote tumor growth. No studies have examined this risk. Dihexa's long half-life compounds the concern — once administered, it remains active for an extended period. No human clinical trials have been conducted [9].
Cerebrolysin is not a single peptide but a complex mixture of low-molecular-weight neuropeptides and free amino acids derived from purified porcine (pig) brain tissue. It is designed to mimic the effects of endogenous neurotrophic factors, and its small peptide components can cross the blood-brain barrier [12].
Cerebrolysin is approved in many European and Asian countries for stroke, TBI, and dementia. It has been studied in over 200 clinical trials involving more than 15,000 patients [12].
Alzheimer's disease. Multiple trials show small but measurable improvements in Alzheimer's and vascular dementia symptoms. A 2016 study found synergistic BDNF increases in Alzheimer patients treated with Cerebrolysin plus Donepezil, with associated cognitive improvement [12].
Traumatic brain injury. Randomized controlled trials show improvements in motor skills, cognitive abilities, and functional outcomes in TBI patients. Over 10 published studies have examined Cerebrolysin in more than 1,900 TBI patients [13].
Stroke recovery. Some trials show improved 90-day functional outcomes in acute ischemic stroke. However, the Cochrane Review raised concerns that benefits may be limited and Cerebrolysin may increase the risk of serious non-fatal adverse events [12].
Mechanism. Cerebrolysin inhibits apoptosis, modulates synaptic plasticity, reduces inflammation via the CREB/PGC-1a pathway, protects against glutamate excitotoxicity, and promotes neurogenesis in damaged brain regions [13].
Cerebrolysin requires intravenous administration and is not approved in the United States. Clinical evidence supports its use in neurological recovery, but data on cognitive enhancement in healthy adults is limited.
